TOP TIERMARKET NEWSWIRE

News & sentiment

CELLECTIS S A ADR (CLLS) — News & AI sentiment

CELLECTIS S A ADR (CLLS) news roundup. 4 stories in the past week, 7 over 30 days. Average 30-day sentiment is 49.7/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

4

avg sentiment 61.5/100

30d stories

7

avg sentiment 49.7/100

Insider net (90d)

$0

0 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

CLLS news in the last 24 hours, 7 days, 30 days and 90 days

How much CLLS coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	CLLS stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	4	61.5/100	CLLS headlines →
Last 30 days	7	49.7/100	CLLS headlines →
Last 90 days	39	46.7/100	CLLS headlines →

Latest stories on CLLS

Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026

Business Insider64 · neutralproduct/pr

3d ago

Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026

GlobeNewswire63 · neutralproduct/pr

3d ago

Cellectis raises FY26 adjusted EPS view to $11.55 from $11.30, consensus $11.15

The Fly64 · neutralearnings

4d ago

Cellectis sees Q4 adjusted EPS $3.37-$3.57

The Fly55 · neutralearnings

4d ago

Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

GlobeNewswire34 · bearishgeneral

Oct 15

Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

GlobeNewswire34 · bearishgeneral

Oct 15

Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

GlobeNewswire34 · bearishgeneral

Oct 14

CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law

Barchart50 · neutralgeneral

Sep 19

CLLS INVESTOR ALERT: Investigation of Cellectis S.A. Announced by Holzer & Holzer, LLC

GlobeNewswire50 · neutralgeneral

Sep 17

Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Barchart34 · bearishgeneral

Sep 17

Cellectis (CLLS) Exits Two CAR-T Programs. Can Gene Editing Justify the Clinical Reset?

Yahoo Top42 · neutralgeneral

Sep 17

Cellectis stock tumbles after Barclays double downgrade

Investing.com Markets32 · bearishanalyst

Sep 16

Cellectis: An 'All Or Nothing' Pivot To In-Vivo Gene Editing Is Worth Monitoring

Seeking Alpha52 · neutralproduct/pr

Sep 16

Cellectis downgraded to Underweight from Overweight at Barclays

The Fly34 · bearishanalyst

Sep 16

Barclays cuts Cellectis stock rating on gene editing concerns

Investing.com Analyst Ratings34 · bearishanalyst

Sep 16

Cellectis falls as Citizens downgrades on pivot to genetic medicines

Seeking Alpha34 · bearishanalyst

Sep 15

CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot

Stocktwits News32 · bearishgeneral

Sep 15

Cellectis price target lowered to $8 from $10 at Baird

The Fly34 · bearishanalyst

Sep 15

Cellectis price target lowered to $3 from $4 at Wells Fargo

The Fly34 · bearishanalyst

Sep 15

Cellectis downgraded to Market Perform from Outperform at Citizens

The Fly38 · neutralanalyst

Sep 15

Citizens downgrades Cellectis stock rating on strategy shift

Investing.com Analyst Ratings34 · bearishanalyst

Sep 15

Cellectis S.A. (CLLS) Discusses Strategic Transformation and In Vivo Gene Editing Pipeline Update Transcript

Seeking Alpha63 · neutralproduct/pr

Sep 14

At a glance: stocks gapping down premarket

Seeking Alpha34 · bearishgeneral

Sep 14

Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company

GlobeNewswire65 · bullishproduct/pr

Sep 14

Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company

Business Insider63 · neutralproduct/pr

Sep 14

Open CLLS in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →